Claude Perreault
Overview
Explore the profile of Claude Perreault including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
120
Citations
2845
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kina E, Larouche J, Thibault P, Perreault C
Trends Genet
. 2024 Oct;
41(2):162-169.
PMID: 39389870
Peptides presented by MHC proteins regulate all aspects of T cell biology. These MHC-associated peptides (MAPs) form what is known as the immunopeptidome and their comprehensive analysis has catalyzed the...
2.
Mathe J, Brochu S, Adam D, Brochiero E, Perreault C
Physiol Rep
. 2024 Sep;
12(17):e70025.
PMID: 39223101
Major histocompatibility complex class I (MHC I) molecules present peptides to CD8+ T-cells for immunosurveillance of infection and cancer. Recent studies indicate lineage-specific heterogeneity in MHC I expression. While respiratory...
3.
Hesnard L, Theriault C, Cahuzac M, Durette C, Vincent K, Hardy M, et al.
Curr Oncol
. 2024 Jun;
31(6):3099-3121.
PMID: 38920720
Epithelial ovarian cancer (EOC) has not significantly benefited from advances in immunotherapy, mainly because of the lack of well-defined actionable antigen targets. Using proteogenomic analyses of primary EOC tumors, we...
4.
Larouche J, Laumont C, Trofimov A, Vincent K, Hesnard L, Brochu S, et al.
Elife
. 2024 Apr;
12.
PMID: 38635416
Transposable elements (TEs) are repetitive sequences representing ~45% of the human and mouse genomes and are highly expressed by medullary thymic epithelial cells (mTECs). In this study, we investigated the...
5.
Noronha N, Durette C, Cahuzac M, E Silva B, Courtois J, Humeau J, et al.
Leukemia
. 2024 Apr;
38(5):1019-1031.
PMID: 38627586
The hypomethylating agent 5-azacytidine (AZA) is the first-line treatment for AML patients unfit for intensive chemotherapy. The effect of AZA results in part from T-cell cytotoxic responses against MHC-I-associated peptides...
6.
Briere R, Emond M, Benhamed A, Blanchard P, Golbon B, Shellenberger J, et al.
Can J Surg
. 2024 Jan;
66(6 Suppl 1):S54-S136.
PMID: 38173057
No abstract available.
7.
Kina E, Laverdure J, Durette C, Lanoix J, Courcelles M, Zhao Q, et al.
J Clin Invest
. 2023 Oct;
134(1).
PMID: 37906288
Hormone receptor-positive breast cancer (HR+) is immunologically cold and has not benefited from advances in immunotherapy. In contrast, subsets of triple-negative breast cancer (TNBC) display high leukocytic infiltration and respond...
8.
Apavaloaei A, Perreault C
Nat Cancer
. 2023 Oct;
4(10):1403-1405.
PMID: 37783806
No abstract available.
9.
Ruiz Cuevas M, Hardy M, Larouche J, Apavaloaei A, Kina E, Vincent K, et al.
Genome Biol
. 2023 Aug;
24(1):188.
PMID: 37582761
MHC-I-associated peptides deriving from non-coding genomic regions and mutations can generate tumor-specific antigens, including neoantigens. Quantifying tumor-specific antigens' RNA expression in malignant and benign tissues is critical for discriminating actionable...
10.